Browse All

Current Filters

CLEAR FILTER x

TITLE

Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Author:Leist, Thomas   Hauser, Stephen   Derfuss, Tobias   Wiendl, Heinz   Arnold, Douglas   Montalban, Xavier   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Ziemssen, Tjalf   

Session Name:S42: Multiple Sclerosis: Biomarkers/Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:S42.003  

Author Institution:Thomas Jefferson University, Philadelphia, PA, USA, Philadelphia, PA  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, Montreal, QC, Canada  Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland , Basel, Switzerland  Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany  

Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial

Author:Steinman, Lawrence   Selmaj, Krzysztof   Comi, Giancarlo   Bar-Or, Amit   Arnold, Douglas   Hartung, Hans-Peter   Montalban, Xavier   Havrdova, Eva   Sheffield, James   Cheng, Chun-Yen   Reardon, Jennifer   Riolo, Jon   Deboer, Erik   Kappos, Ludwig   Cohen, Jeffrey   Cree, Bruce   

Session Name:P2: Multiple Sclerosis: Clinical Practice and Decision Making 2  

Topic:Multiple Sclerosis  

Program Number:P2.007  

Author Institution:Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Center for Neurology, Lódz, Poland, and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Lodz, Poland  Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montreal, QC, Canada  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic, Prague, Czech Republic  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  

Use of a Machine Learning Model to Predict Disability Progression in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod

Author:Kappos, Ludwig   Arnold, Douglas   Pachai, Chahin   Eddy, Nathanial   Osik, Jason   Cheng, Chun-Yen   Harris, Sarah   Deboer, Erik   Freeman, Leorah   Granziera, Cristina   Filippi, Massimo   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.006  

Author Institution:Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montreal, QC, Canada  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Dell Medical School, The University of Texas at Austin, Austin, Texas, Austin, TX  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland  Department of Neurology, University Hospital Basel, Switzerland  Neuroimaging Research Unit, Division of Neuroscience, Neurology Unit Neurorehabilitation Unit, and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy, Milan, Italy  

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials

Author:Cross, Anne   Ziemssen, Tjalf   Arnold, Douglas   Thouvenot, Eric   Zamvil, Scott   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Wiendl, Heinz   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.011  

Author Institution:Washington University School of Medicine, Saint Louis, MO, USA, Saint Louis, MO  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany, Dresden, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  Department of Neurology, Centre Hospitalier Universitaire (CHU) Nîmes, University of Montpellier, Nîmes, France  Institut de Génomique Fonctionnelle, UMR, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Montpellier, Montpellier, France, Nimes Cedex 9, France  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA, San Francisco, CA  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO, USA, Aurora, CO  University of Münster, Münster, Germany, Muenster, Germany  

Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels

Author:Pardo, Gabriel   Kappos, Ludwig   Cross, Anne   Kuhle, Jens   Montalban, Xavier   Khachanova, Natalia   Bhatt, Alit   Piccolo, Rebecca   Xi, Jing   Boer, Ibolya   Arnold, Douglas   Alvarez, Enrique   Ziemssen, Tjalf   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.008  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK  RC2NB, University Hospital Basel, Basel, Switzerland  Washington University School of Medicine, Clayton, MO  Neurologic Clinic and Policlinic and MS Center, Basel, Switzerland  Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, Barcelona, Spain  Russian National Research Medical University N.I. Pirgov, Moscow, Russian Federation  Novartis Healthcare Pvt. Ltd, Hyderabad, India  Novartis Pharmaceuticals Corporation, West Roxbury, MA  Novartis, Shanghai, China, People's Republic of  Novartis Pharma AG, Basel, Switzerland  Montreal Neurological Institute, McGill Univ, Montreal, QC, Canada  University of Colorado, Aurora, CO  University Clinic Dresden, Dresden, Germany